Skip to main content
Top
Published in: Clinical Rheumatology 1/2012

01-01-2012 | Case Based Review

Schnitzler's syndrome associated with pancreatitis: a disease of IL-1 dysregulation

Authors: Cecilia A. Larocca, John W. McEvoy, Carla L. Ellis, Jacqueline Junkins-Hopkins, Todd Kolb, Alan N. Baer, Brian T. Garibaldi

Published in: Clinical Rheumatology | Issue 1/2012

Login to get access

Abstract

Schnitzler's syndrome (SS) is a rare inflammatory disease of unknown origin characterized by chronic urticaria and monoclonal gammopathy (usually IgM) associated with at least two of the following components: fever, arthralgia or arthritis, bone pain, hepato- and/or splenomegaly, lymphadenopathy, elevated erythrocyte sedimentation rate, leukocytosis, and/or abnormal findings on bone morphological investigations. To date, about 100 cases have been described with only 4 being reported in the USA. The mean time to diagnosis from the onset of disease is 5.4 years, given the varied symptoms with which patients may present. The pathogenesis of SS remains unknown but likely involves dysregulation of the IL-1 pathway. We describe here a 48-year-old woman with a monoclonal IgM gammopathy and a 3-year history of chronic pruritic urticarial dermatosis, unexplained fevers, chronic polyarthritis, lymphadenopathy, leukocytosis, hepatomegaly, and weight loss. She also had a history of chronic pancreatitis as well as a family history of recurrent pancreatitis. The diagnosis of Schnitzler's syndrome was made, and she was successfully treated with the IL-1 receptor antagonist, anakinra.
Literature
1.
go back to reference Lipsker D, Veran Y, Grunenberger F, Cribier B, Heid E, Grosshans E (2001) The Schnitzler syndrome. Four new cases and review of the literature. Medicine (Baltimore) 80:37–44CrossRef Lipsker D, Veran Y, Grunenberger F, Cribier B, Heid E, Grosshans E (2001) The Schnitzler syndrome. Four new cases and review of the literature. Medicine (Baltimore) 80:37–44CrossRef
2.
go back to reference de Koning HD, Bodar EJ, van der Meer JW, Simon A, Schnitzler Syndrome Study Group (2007) Schnitzler syndrome: beyond the case reports: review and follow-up of 94 patients with an emphasis on prognosis and treatment. Semin Arthritis Rheum 37:137–148PubMedCrossRef de Koning HD, Bodar EJ, van der Meer JW, Simon A, Schnitzler Syndrome Study Group (2007) Schnitzler syndrome: beyond the case reports: review and follow-up of 94 patients with an emphasis on prognosis and treatment. Semin Arthritis Rheum 37:137–148PubMedCrossRef
3.
go back to reference Dinarello CA (2009) Interleukin-1beta and the autoinflammatory diseases. N Engl J Med 360:2467–2470PubMedCrossRef Dinarello CA (2009) Interleukin-1beta and the autoinflammatory diseases. N Engl J Med 360:2467–2470PubMedCrossRef
4.
go back to reference Gabay C, Lamacchia C, Palmer G (2010) IL-1 pathways in inflammation and human diseases. Nat Rev Rheumatol 6:232–241PubMedCrossRef Gabay C, Lamacchia C, Palmer G (2010) IL-1 pathways in inflammation and human diseases. Nat Rev Rheumatol 6:232–241PubMedCrossRef
5.
go back to reference Aksentijevich I, Masters SL, Ferguson PJ, Dancey P, Frenkel J, van Royen-Kerkhoff A et al (2009) An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med 360:2426–2437PubMedCrossRef Aksentijevich I, Masters SL, Ferguson PJ, Dancey P, Frenkel J, van Royen-Kerkhoff A et al (2009) An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med 360:2426–2437PubMedCrossRef
6.
go back to reference Saurat JH, Schifferli J, Steiger G, Dayer JM, Didierjean L (1991) Antiinterleukin-1 alpha autoantibodies in humans: characterization, isotype distribution and receptor-binding inhibition-higher frequency in Schnitzler's syndrome (urticaria and macroglobulinemia). J Allergy Clin Immunol 88:244–256PubMedCrossRef Saurat JH, Schifferli J, Steiger G, Dayer JM, Didierjean L (1991) Antiinterleukin-1 alpha autoantibodies in humans: characterization, isotype distribution and receptor-binding inhibition-higher frequency in Schnitzler's syndrome (urticaria and macroglobulinemia). J Allergy Clin Immunol 88:244–256PubMedCrossRef
7.
go back to reference Ryan JG, de Koning HD, Beck LA, Booty MG, Kastner DL, Simon A (2008) IL-1 blockade in Schnitzler syndrome: ex vivo findings correlate with clinical remission. J Allergy Clin Immunol 121:260–262PubMedCrossRef Ryan JG, de Koning HD, Beck LA, Booty MG, Kastner DL, Simon A (2008) IL-1 blockade in Schnitzler syndrome: ex vivo findings correlate with clinical remission. J Allergy Clin Immunol 121:260–262PubMedCrossRef
8.
go back to reference de Kleijn EM, Telgt D, Laan R (1997) Schnitzler's syndrome presenting as fever of unknown origin (FUO). The role of cytokines in its systemic features. Neth J Med 51:140–142PubMedCrossRef de Kleijn EM, Telgt D, Laan R (1997) Schnitzler's syndrome presenting as fever of unknown origin (FUO). The role of cytokines in its systemic features. Neth J Med 51:140–142PubMedCrossRef
9.
go back to reference Migliorini P, Corso ID, Tommasi C, Boraschi D (2009) Free circulating interleukin-18 is increased in Schnitzler syndrome: a new autoinflammatory disease? Eur Cytokine Netw 20:108–111PubMed Migliorini P, Corso ID, Tommasi C, Boraschi D (2009) Free circulating interleukin-18 is increased in Schnitzler syndrome: a new autoinflammatory disease? Eur Cytokine Netw 20:108–111PubMed
10.
go back to reference Pizzirani C, Falzoni S, Govoni M, La Corte R, Donadei S, Di Virgilio F et al (2009) Dysfunctional inflammasome in Schnitzler's syndrome. Rheumatology 48:1304–1308PubMedCrossRef Pizzirani C, Falzoni S, Govoni M, La Corte R, Donadei S, Di Virgilio F et al (2009) Dysfunctional inflammasome in Schnitzler's syndrome. Rheumatology 48:1304–1308PubMedCrossRef
11.
go back to reference Loock J, Lamprecht P, Timmann C, Mrowietz U, Csernok E, Gross WL (2010) Genetic predisposition (NLRP3 V198M mutation) for IL-1-mediated inflammation in a patient with Schnitzler syndrome. J All Clin Immunol 125:500–502CrossRef Loock J, Lamprecht P, Timmann C, Mrowietz U, Csernok E, Gross WL (2010) Genetic predisposition (NLRP3 V198M mutation) for IL-1-mediated inflammation in a patient with Schnitzler syndrome. J All Clin Immunol 125:500–502CrossRef
12.
go back to reference Lipsker D, Spehner D, Drillien R, Schmitt P, Cribier B, Heid E et al (2000) Schnitzler syndrome: heterogeneous immunopathological findings involving IgM-skin interactions. Br J Dermatol 142:954–959PubMedCrossRef Lipsker D, Spehner D, Drillien R, Schmitt P, Cribier B, Heid E et al (2000) Schnitzler syndrome: heterogeneous immunopathological findings involving IgM-skin interactions. Br J Dermatol 142:954–959PubMedCrossRef
13.
go back to reference Nashan D, Sunderkötter C, Bonsmann G, Luger T, Goerdt S (1995) Chronic urticaria, arthralgia, raised erythrocyte sedimentation rate and IgG paraproteinaemia: a variant of Schnitzler's syndrome? Br J Dermatol 133:132–134PubMedCrossRef Nashan D, Sunderkötter C, Bonsmann G, Luger T, Goerdt S (1995) Chronic urticaria, arthralgia, raised erythrocyte sedimentation rate and IgG paraproteinaemia: a variant of Schnitzler's syndrome? Br J Dermatol 133:132–134PubMedCrossRef
14.
go back to reference Rizzi R, Curci P, Rinaldi E, Rinaldi F, Cimmino A, Ricco R et al (2008) Schnitzler's syndrome: monoclonal gammopathy associated with chronic urticaria. Acta Haematol 120(1):1–4PubMedCrossRef Rizzi R, Curci P, Rinaldi E, Rinaldi F, Cimmino A, Ricco R et al (2008) Schnitzler's syndrome: monoclonal gammopathy associated with chronic urticaria. Acta Haematol 120(1):1–4PubMedCrossRef
15.
go back to reference Tanneberger O, Büchner S, Zimmerli LU (2007) Schnitzler's syndrome with urticaria vasculitis. Internist (Berl) 48:1432–1435CrossRef Tanneberger O, Büchner S, Zimmerli LU (2007) Schnitzler's syndrome with urticaria vasculitis. Internist (Berl) 48:1432–1435CrossRef
16.
go back to reference Kyle RA, Therneau TM, Rajkumar SV, Remstein ED, Offord JR, Larson DR et al (2003) Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood 102:3759–3764PubMedCrossRef Kyle RA, Therneau TM, Rajkumar SV, Remstein ED, Offord JR, Larson DR et al (2003) Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood 102:3759–3764PubMedCrossRef
17.
go back to reference Verret JL, Leclech C, Rousselet MC, Hurez D, Schnitzler L (1993) Schnitzler syndrome and Waldenström disease. Fatal outcome of the original case. Ann Dermatol Venereol 120:459–460PubMed Verret JL, Leclech C, Rousselet MC, Hurez D, Schnitzler L (1993) Schnitzler syndrome and Waldenström disease. Fatal outcome of the original case. Ann Dermatol Venereol 120:459–460PubMed
18.
go back to reference Blaise S (2003) Sensitive chonic inflammatory demyelinating polyradiculoneuropathy in Schnitzler's syndrome. Ann Dermatol Venereol 130:348–351PubMed Blaise S (2003) Sensitive chonic inflammatory demyelinating polyradiculoneuropathy in Schnitzler's syndrome. Ann Dermatol Venereol 130:348–351PubMed
19.
go back to reference Lebbe C, Rybojad M, Klein F, Oksenhendler E, Catala M, Danon F et al (1994) Schnitzler syndrome associated with sensorimotor neuropathy. J Am Acad Dermatol 30:316–318PubMedCrossRef Lebbe C, Rybojad M, Klein F, Oksenhendler E, Catala M, Danon F et al (1994) Schnitzler syndrome associated with sensorimotor neuropathy. J Am Acad Dermatol 30:316–318PubMedCrossRef
20.
go back to reference Worm M, Kolde G (2003) Schnitzler's syndrome: successful treatment of two patients using thalidomide. Br J Dermatol 148:601–602PubMedCrossRef Worm M, Kolde G (2003) Schnitzler's syndrome: successful treatment of two patients using thalidomide. Br J Dermatol 148:601–602PubMedCrossRef
21.
go back to reference Ramadan KM, Eswedi HA, El-Agnaf MR (2007) Schnitzler syndrome: a case report of successful treatment using the anti-CD20 monoclonal antibody rituximab. Br J Dermatol 156:1072e4CrossRef Ramadan KM, Eswedi HA, El-Agnaf MR (2007) Schnitzler syndrome: a case report of successful treatment using the anti-CD20 monoclonal antibody rituximab. Br J Dermatol 156:1072e4CrossRef
22.
go back to reference Murota H, Shoda Y, Ishibashi T, Sugahara H, Matsumura I, Katayama I (2009) Improvement of recurrent urticaria in a patient with Schnitzler syndrome associated with B-cell lymphoma with combination rituximab and radiotherapy. J Am Acad Derm 61:1070–1075PubMedCrossRef Murota H, Shoda Y, Ishibashi T, Sugahara H, Matsumura I, Katayama I (2009) Improvement of recurrent urticaria in a patient with Schnitzler syndrome associated with B-cell lymphoma with combination rituximab and radiotherapy. J Am Acad Derm 61:1070–1075PubMedCrossRef
23.
go back to reference Besada E, Nossent H (2010) Dramatic response to IL1-RA treatment in longstanding multidrug resistant Schnitzler's syndrome: a case report and literature review. Clin Rheumatol 29:567–571PubMedCrossRef Besada E, Nossent H (2010) Dramatic response to IL1-RA treatment in longstanding multidrug resistant Schnitzler's syndrome: a case report and literature review. Clin Rheumatol 29:567–571PubMedCrossRef
24.
go back to reference Mertens M, Singh JA (2009) Anakinra for rheumatoid arthritis. Cochrane Database Syst Rev 1:CD005121PubMed Mertens M, Singh JA (2009) Anakinra for rheumatoid arthritis. Cochrane Database Syst Rev 1:CD005121PubMed
25.
go back to reference Sediva A, Polouckova A, Podrazil M, Fronkova E, Kalina T (2010) Characterization of the B-cell compartment in a patient with Schnitzler syndrome. Scand J Rheumatol 0:1–3 Sediva A, Polouckova A, Podrazil M, Fronkova E, Kalina T (2010) Characterization of the B-cell compartment in a patient with Schnitzler syndrome. Scand J Rheumatol 0:1–3
26.
go back to reference Lust JA, Lacy M, Zeldenrust SR, Dispenzieri A, Gertz M, Witzig TE et al (2009) Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1β-induced interleukin-6 production and the myeloma proliferative component. Mayo Clin Proc 84:114–122PubMedCrossRef Lust JA, Lacy M, Zeldenrust SR, Dispenzieri A, Gertz M, Witzig TE et al (2009) Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1β-induced interleukin-6 production and the myeloma proliferative component. Mayo Clin Proc 84:114–122PubMedCrossRef
27.
go back to reference Dinarello C (2009) Targeting the pathogenic role of interleukin 1β in the progression of smoldering/indolent myeloma to active disease. Mayo Clin Proc 84:105–107PubMedCrossRef Dinarello C (2009) Targeting the pathogenic role of interleukin 1β in the progression of smoldering/indolent myeloma to active disease. Mayo Clin Proc 84:105–107PubMedCrossRef
28.
go back to reference Nishida A, Andoh A, Imaeda H, Inatomi O, Shiomi H, Fujiyama Y (2010) Expression of interleukin 1-like cytokine interleukin 33 and its receptor complex (ST2L and IL1RAcP) in human pancreatic myofibroblasts. Gut 59:531–541PubMedCrossRef Nishida A, Andoh A, Imaeda H, Inatomi O, Shiomi H, Fujiyama Y (2010) Expression of interleukin 1-like cytokine interleukin 33 and its receptor complex (ST2L and IL1RAcP) in human pancreatic myofibroblasts. Gut 59:531–541PubMedCrossRef
29.
go back to reference Smithies AM, Sargen K, Demaine AG, Kingsnorth AN (2000) Investigation of the interleukin 1 gene cluster and its association with acute pancreatitis. Pancreas 20:234–240PubMedCrossRef Smithies AM, Sargen K, Demaine AG, Kingsnorth AN (2000) Investigation of the interleukin 1 gene cluster and its association with acute pancreatitis. Pancreas 20:234–240PubMedCrossRef
30.
go back to reference Norman J (1995) Interleukin-1 receptor antagonist decreases severity of experimental acute pancreatitis. Surgery 117:648–655PubMedCrossRef Norman J (1995) Interleukin-1 receptor antagonist decreases severity of experimental acute pancreatitis. Surgery 117:648–655PubMedCrossRef
Metadata
Title
Schnitzler's syndrome associated with pancreatitis: a disease of IL-1 dysregulation
Authors
Cecilia A. Larocca
John W. McEvoy
Carla L. Ellis
Jacqueline Junkins-Hopkins
Todd Kolb
Alan N. Baer
Brian T. Garibaldi
Publication date
01-01-2012
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 1/2012
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-011-1804-4

Other articles of this Issue 1/2012

Clinical Rheumatology 1/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine